Compare NCPL & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCPL | LYRA |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.6M |
| IPO Year | N/A | 2020 |
| Metric | NCPL | LYRA |
|---|---|---|
| Price | $0.69 | $1.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 1.7M | 102.7K |
| Earning Date | 12-15-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $797,839.00 | $600,000.00 |
| Revenue This Year | $739.37 | N/A |
| Revenue Next Year | N/A | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.61 | $1.63 |
| 52 Week High | $8.75 | $37.50 |
| Indicator | NCPL | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 27.52 |
| Support Level | $0.72 | $1.63 |
| Resistance Level | $0.89 | $3.94 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 27.78 | 15.37 |
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.